Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 72 points (-0.5%) at 15,564 as of Friday, Sept. 20, 2013, 12:54 PM ET. The NYSE advances/declines ratio sits at 854 issues advancing vs. 2,087 declining with 92 unchanged. The Drugs industry currently sits down 0.5% versus the S&P 500, which is down 0.4%. Top gainers within the industry include Allergan ( AGN), up 1.7%, Shire ( SHPG), up 1.1%, Alexion Pharmaceuticals ( ALXN), up 1.1%, GlaxoSmithKline ( GSK), up 0.7% and Sanofi ( SNY), up 0.7%. On the negative front, top decliners within the industry include Regeneron Pharmaceuticals ( REGN), down 0.9%, and Valeant Pharmaceuticals International ( VRX), down 0.9%. TheStreet would like to highlight 5 stocks pushing the industry higher today: 5. Sarepta Therapeutics ( SRPT) is one of the companies pushing the Drugs industry higher today. As of noon trading, Sarepta Therapeutics is up $5.70 (15.5%) to $42.39 on heavy volume. Thus far, 8.9 million shares of Sarepta Therapeutics exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $36.07-$43.60 after having opened the day at $37.79 as compared to the previous trading day's close of $36.69. Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Sarepta Therapeutics has a market cap of $1.2 billion and is part of the health care sector. Shares are up 43.5% year to date as of the close of trading on Thursday. Currently there are 9 analysts that rate Sarepta Therapeutics a buy, no analysts rate it a sell, and 4 rate it a hold. TheStreet Ratings rates Sarepta Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Sarepta Therapeutics Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.